PANoptosis opens new treatment options for allergic bronchopulmonary aspergillosis
- PMID: 39170913
- PMCID: PMC11338086
- DOI: 10.1016/j.jacig.2024.100298
PANoptosis opens new treatment options for allergic bronchopulmonary aspergillosis
Abstract
Background: Allergic bronchopulmonary aspergillosis (ABPA) is a rare airway disorder primarily affecting patients with asthma and cystic fibrosis. Persistent airway inflammation brought on by Aspergillus fumigatus exacerbates the underlying condition and can cause significant respiratory damage. Treatments center on reducing inflammation with the use of corticosteroids and antifungals. PANoptosis is a new concept in the field of cell death and inflammation that posits the existence of cross talk and a master control system for the 3 programmed cell death (PCD) pathways, namely, apoptosis, pyroptosis, and necroptosis. This concept has revolutionized the understanding of PCD and opened new avenues for its exploration. Studies show that Aspergillus is one of the pathogens that is capable of activating PANoptosis via the Z-DNA binding protein 1 (ZBP1) pathway and plays an active role in the inflammation caused by this organism.
Objective: This article explores the nature of inflammation in ABPA and ways in which PCD could lead to novel treatment options.
Method: PubMed was used to review the literature surrounding Aspergillus infection-related inflammation and PANoptosis.
Results: There is evidence that apoptosis and pyroptosis protect against Aspergillus-induced inflammation, whereas necroptosis promotes inflammation.
Conclusion: Experimental medications, in particular, necroptosis inhibitors such as necrosulfonamide and necrostatin-1, should be studied for use in the treatment of ABPA.
Keywords: ABPA; Aspergillus fumigatus; PANoptosis; TAK1; ZBP1; allergic bronchopulmonary aspergillosis; apoptosis; necroptosis; programmed cell death; pyroptosis.
© 2024 The Authors.
Conflict of interest statement
The N. Kolliputi laboratory is funded by the Joy McCann Culverhouse endowment to the Division of Allergy and Immunology. Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.
Figures


References
-
- Asano K., Hebisawa A., Ishiguro T., Takayanagi N., Nakamura Y., Suzuki J., et al. New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation. J Allergy Clin Immunol. 2021;147:1261–1268.e5. - PubMed
-
- Denning D.W., Pleuvry A., Cole D.C. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2013;51:361–370. - PubMed
-
- Maturu V.N., Agarwal R. Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis. Clin Exp Allergy. 2015;45:1765–1778. - PubMed
-
- Roboubi A., Audousset C., Frealle E., Brun A.L., Laurent F., Vitte J., et al. Allergic bronchopulmonary aspergillosis: a multidisciplinary review. J Mycol Med. 2023;33 - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous